A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma by Xing Jin, Zhengyang Hu, Qihai Sui, Mengnan Zhao, Jiaqi Liang, Zhenyu Liao, Yuansheng Zheng, Hao Wang, Yu Shi

“…The tumor immune microenvironment (TIME) played an important role in immunotherapy prognosis and treatment response. Immune cells constitute a large part of the tumor microenvironment and regulate tumor progression. …”
Get full text

Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency by Anna Roppelt, Ulyana Markina, Irina Beloglazova, Irina Beloglazova, Vasily Parshin, Dmitry Kanner, Dmitry Pershin, Mariia Fadeeva, Elena Raykina, Maxim Aleksenko, Alexander Karaulov, Mariana Lysenko, Mariana Lysenko, Daria Fomina, Daria Fomina, Daria Fomina

Get full text

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy by Jiawei Wang, Yan Bao, Yandan Yao

“…Immune checkpoint blockade therapy and chimeric antigen receptor T-cell (CAR-T) immunotherapy are clinically effective in a variety of cancers. …”
Get full text

New T-lymphocyte subpopulations and their characteristics: Challenges to the classical division of lymphocyte function by Filip Lewandowski, Paulina Niedźwiedzka-Rystwej

“…Additionally, newly identified cytotoxic T-cell subsets, such as CD8 + CD39 + and CD8 + CD28 + cells, demonstrate unique effector properties with potential therapeutic applications in cancer immunotherapy. Furthermore, the discovery of CD20 + T cells challenges traditional views, offering new avenues for immunotherapy in cancer, autoimmune disorders, and infectious diseases. …”
Get full text

Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases by Yuming Lu, Yifan Wang, Tiantian Ruan, Yihan Wang, Linling Ju, Mengya Zhou, Luyin Liu, Dengfu Yao, Min Yao

“…Given the unique immunoregulatory abilities of Tregs, the development of targeted therapeutic drugs may position them as novel targets in immunotherapy. This could contribute to restoring immune system balance, resolving metabolic dysregulation, and fostering innovation and progress in immunotherapy.…”
Get full text

Theoretical Modeling Techniques and Their Impact on Tumor Immunology by Anna Lena Woelke, Manuela S. Murgueitio, Robert Preissner

“…While conventional cancer treatment usually results in the patient suffering from severe side effects, immunotherapy is a promising alternative. Nevertheless, some questions remain unanswered with regard to using immunotherapy to treat cancer hindering it from being widely established. …”
Get full text

Contribution of Gut Microbiota to Immune Tolerance in Infants by Constanza S. Méndez, Susan M. Bueno, Alexis M. Kalergis

Get full text

A Patient with Double-Negative VGKC, Peripheral Nerve Hyperexcitability, and Central Nervous System Symptoms: A Postinfectious Autoimmune Disease by Birte Eikeland

“…The disease started acutely one month after an episode of enteroviral pericarditis and responded well to immunotherapy. The patient is presumed to have developed a postinfectious immunotherapy-responsive autoimmune disease. …”
Get full text

The heterogeneity of NOTCH1 to tumor immune infiltration in pan-cancer by XiaoJun Duan, Rihan Wu, Mingyang Zhang, Kexin Li, Lei Yu, Huirong Sun, Xingxia Hao, Changshan Wang

“…Pharmacological regulation of NOTCH1 is promising in tumor immunotherapy, whereas the effective rate of existing therapies remains low. …”
Get full text

Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer:... by Joachim G J V Aerts, Sjoerd H van der Burg, Martijn P Lolkema, Sai Ping Lau, Freek R van ’t Land, Marjolein Y V Homs, Casper H J van Eijck

“…Introduction The prognosis of patients with advanced pancreatic ductal adenocarcinoma (PDAC) is dismal and conventional chemotherapy treatment delivers limited survival improvement. Immunotherapy may complement our current treatment strategies. …”
Get full text

Tumor-associated-fibrosis and active collagen-CD44 axis characterize a poor-prognosis subtype of gastric cancer and contribute to tumor immunosuppression by Yingqi Yang, Haohan Sun, Hongkai Yu, Luyao Wang, Chang Gao, Haokun Mei, Xiaomeng Jiang, Minghui Ji

“…By combining it with immune checkpoint inhibitors (ICIs), it may improve the efficacy of immunotherapy for gastric cancer and offer new hope for treatment.…”
Get full text

Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects by Zhi-Xun Guo, Jia-Li Ma, Jin-Qiu Zhang, Ling-Ling Yan, Ying Zhou, Xin-li Mao, Xin-li Mao, Xin-li Mao, Shao-Wei Li, Shao-Wei Li, Shao-Wei Li, Xian-Bin Zhou, Xian-Bin Zhou, Xian-Bin Zhou

“…The optimization of these immunotherapies requires further investigation. Mounting evidence underscores the importance of modulating metabolic traits within the tumor microenvironment (TME) to augment anti-tumor immunotherapy.MethodsWe selected relevant studies on the metabolism of the esophageal cancer tumor microenvironment and immune cells based on our searches of MEDLINE and PubMed, focusing on screening experimental articles and reviews related to glucose metabolism, amino acid metabolism, and lipid metabolism, as well their interactions with tumor cells and immune cells, published within the last five years. …”
Get full text

Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers by Zhihao Lu, Mingfei Geng, Yongtao Han, Jianzhong Cao, Jun Wang, Tianshu Liu, Xianglin Yuan, Xue Meng, Yanqiao Zhang, Rong Zhao, Lixin Wan, Enxiao Li, Wenran Wang, Zhijie Li, Danfeng Shi, Jing Qian, Si Shi, Fengshi Dong, Lin Shen

“…These findings highlight the need for novel EC treatments before immunotherapy was introduced, and provide a baseline for evaluating the benefits of immunotherapy, now that this treatment is widely used in this setting.…”
Get full text

The prognostic significance of tertiary lymphoid structures in oral squamous cell carcinomas: a systematic review by V. Ribeiro, J-L. Teillaud, J-L. Teillaud, J-L. Teillaud, M-C. Dieu-Nosjean, M-C. Dieu-Nosjean, M-C. Dieu-Nosjean, G. Lescaille, G. Lescaille, G. Lescaille, G. Lescaille, G. Lescaille, J. Rochefort, J. Rochefort, J. Rochefort, J. Rochefort, J. Rochefort

Get full text

Immune infiltrate populations within distinct tumor immune microenvironments predictive of immune checkpoint treatment outcome by Brian Z Ring, Catherine T. Cronister, Huijun Z. Ring, Douglas T. Ross, Robert S. Seitz

“…One signature, which contained multiple B-cell markers, was associated with immunotherapy efficacy in three cohorts, including IMvigor210. …”
Get full text

Multiple Factors Determine the Oncolytic or Carcinogenic Effects of TLRs Activation in Cancer by Yingxiang Yang, Chengyue Jin, Anthony Yeo, Bo Jin

“…In this review, the potential therapeutic value of TLRs in immunotherapy and its role in oncogenesis are explored. …”
Get full text

The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment by Ze-Tao Zhan, Lu Liu, Ming-Zhen Cheng, Yi Gao, Wei-Jie Zhou

“…These patients need to take antidiabetic drugs while receiving antitumor drugs therapy. Recently, immunotherapy offers significant advances for cancer treatment. …”
Get full text

KIF26B and CREB3L1 Derived from Immunoscore Could Inhibit the Progression of Ovarian Cancer by Shanshan Cong, Yao Fu, Xibo Zhao, Qiuyan Guo, Tian Liang, Di Wu, Jing Wang, Guangmei Zhang

“…KIF26B and CREB3L1 are expected to be potential targets for the immunotherapy of OV.…”
Get full text

Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors by Giorgia Anastasio, Michela Felaco, Alessia Lamolinara, Francesco del Pizzo, Elisa Cacciagrano, Carla Mottini, Margherita Mutarelli, Francesca Di Modugno, Manuela Iezzi, Luca Cardone

Get full text

A high-valence bismuth(V) nanoplatform triggers cancer cell death and anti-tumor immune responses with exogenous excitation-free endogenous H2O2- and O2-independent ROS generation by Yizhang Tang, Xujiang Yu, Liangrui He, Meng Tang, Wenji Yue, Ruitong Chen, Jie Zhao, Qi Pan, Wanwan Li

“…Abstract Reactive oxygen species with evoked immunotherapy holds tremendous promise for cancer treatment but has limitations due to its dependence on exogenous excitation and/or endogenous H2O2 and O2. …”
Get full text